Previous close | 8.22 |
Open | 8.15 |
Bid | 8.10 x 3200 |
Ask | 8.11 x 2200 |
Day's range | 8.08 - 8.32 |
52-week range | 5.28 - 13.44 |
Volume | |
Avg. volume | 4,801,107 |
Market cap | 1.833B |
Beta (5Y monthly) | 0.20 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.40 |
Earnings date | 02 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 22.38 |
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had approved its biologics license application (BLA) for lifileucel, as a combination therapy with Merck's Keytruda (pembrolizumab) to treat advanced melanoma. Iovance specializes in using tumor-infiltrating lymphocytes as therapies to fight cancer cells. Iovance announced on late Friday that the FDA had granted lifileucel Priority Review status and set a Prescription Drug User Fee Act (PDUFA) date of Nov. 25 for the cell therapy.
The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.
Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.
What happened Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up by more than 14% late Monday afternoon. There were two factors that brought the clinical-stage biotech company's shares up Monday.
After a dreadful 2022, growth stocks have started to rebound in 2023. The tech-heavy Nasdaq Composite has gained a healthy 15.4% so far this year. For example, Wall Street analysts think small-cap biotechs Iovance Biotherapeutics (NASDAQ: IOVA) and Seres Therapeutics (NASDAQ: MCRB) could see a parabolic rise in their respective share prices in 2023.
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.
Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.
Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.
Iovance (IOVA) to acquire worldwide rights to an IL-2 product already approved by FDA for two cancer indications. The deal is expected to close by first-quarter 2023.
Investors were more than cheered by a business update from cancer-focused biotech Iovance Biotherapeutics (NASDAQ: IOVA) on Monday. For Proleukin, an interleukin-2 molecule used to stimulate T-cell activity in the fight against cancer, Iovance is making an upfront payment of 166.7 million British pounds ($206.6 million). It is also on the hook for a 41.7 million pound ($51.7 million) milestone payment upon first approval of its leading pipeline therapy, advanced melanoma treatment Lifileucel, and what it described only as double-digit worldwide sales royalties derived from Proleukin.
Post FDA's feedback on lifileucel, Iovance (IOVA) extends its timeline to complete the rolling BLA submission for lifileucel in melanoma. It expects to complete the filing in the first quarter.
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) doses the first patient in phase I/II study evaluating its TIL therapy candidate, IOV-4001, in adults with metastatic melanoma and NSCLC.
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.
Iovance (IOVA) starts a rolling BLA submission with the FDA seeking approval for its lead pipeline candidate in advanced melanoma patients. The filing is expected to be completed by fourth-quarter 2022.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma, this August.